Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside

HEBERSaVax is a cancer therapeutic vaccine candidate based on the combination of a recombinant antigen representative of human vascular endothelial growth factor (VEGF), and clinically tested adjuvants. The vaccine has been shown to inhibit tumor growth and metastases in mice, and to induce VEGF-blo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in oncology 2018-01, Vol.45 (1-2), p.68-74
Hauptverfasser:	Morera-Díaz, Yanelys, Gavilondo, Jorge V., Bequet-Romero, Mónica, Sánchez Ramírez, Javier, Hernández-Bernal, Francisco, Selman-Housein, Katty-Hind, Perez, Lincidio, Ayala-Ávila, Marta
Format:	Artikel
Sprache:	eng
Schlagworte:	HEBERSaVax VEGF blocking VEGF vaccine VEGFR
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!